Natural killer cell-based senotherapy: a promising strategy for healthy aging.
Nakazawa T, Yamanishi R, Morimoto T, Matsuda R. Frontiers in Immunology. 16. 2025

Immunotherapy using allogenic NK cells downregulates mitochondrial-related genes and inhibits the OXPHOS system of malignant meningioma.
Maeoka R, Matsuda R, Nakazawa T, Mochida Y, Ouji-Sageshima N, Yamada K, Morimoto T, Takeshima Y, Yamada S, Nishimura F, Park YS, Ito T, Nakagawa I. Biomed Pharmacother. 187, 11809. 2025

Characterization of HIF-1α Knockout Primary Human Natural Killer Cells including Populations in Allogeneic Glioblastoma.
Nakazawa T, Morimoto T, Maeoka R, Yamada K, Matsuda R, Nakamura M, Nishimura F, Yamada S, Park YS, Tsujimura T, Nakagawa I.
Int. J. Mol. Sci. 25(11), 5896 2024

Bulk RNA sequencing reveals the comprehensive genetic characteristics of human cord blood-derived natural killer cells.
Morimoto T, Nakazawa T, Matsuda R, Maeoka R, Nishimura F, Nakamura M, Yamada S, Nakagawa I, Park YS, Tsujimura T
Regen Ther. 25:367-376. 2024

Antitumor effects of intravenous natural killer cell infusion in an orthotopic glioblastoma xenograft murine model and gene expression profile analysis.
Morimoto T, Nakazawa T, Matsuda R, Maeoka R, Nishimura F, Nakamura M, Yamada S, Tsujimura T, Park YS, Nakagawa I
Int J Mol Sci. 25(4), 2435 2024

Therapeutic anti-KIR antibody of 1-7F9 attenuates the anti-tumor effects of expanded and activated human primary natural killer cells on in vitro glioblastoma-like cells and orthotopic tumors derived therefrom.
Maeoka R, Nakazawa T, Matsuda R, Morimoto T, Shida Y, Nakamura M, Nishimura F, Yamada S, Nakagawa I, Park YS, Tsujimura T, Nakase H.
Int J Mol Sci. 24(18), 14183 2023

Local administration of shikonin improved the overall survival in orthotopic murine glioblastoma models with temozolomide resistance.
Maeoka R, Ouji Y, Nakazawa T, Matsuda R, Morimoto T, Yokoyama S, Yamada S, Nishimura F, Nakagawa I, Park YS, Yoshikawa M, Nakase H.
Biomed Pharmacother. 166; 115296 2023

CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma.
Nakazawa T, Morimoto T, Maeoka R, Matsuda R, Nakamura M, Nishimura F, Ouji N, Yamada S, Nakagawa I, Park YS, Ito T, Nakase H, Tsujimura T.
J Exp Clin Cancer Res. 42, 205. 2023

An Efficient Feeder-free and Chemically-defined Expansion Strategy for Highly Purified Natural Killer Cells Derived from Human Cord Blood. Nakazawa T, Maeoka R, Morimoto T, Matsuda R, Nakamura M, Nishimura F, Yamada S, Nakagawa I, Park YS, Ito T, Nakase H, Tsujimura T. Regen Ther. 24: 32-42. 2023

Does ghrelin regulate intestinal motility in rabbits? An in vitro study using isolated duodenal strips.
Zhang S, Kaiya H, Kitazawa T.
Gen Comp Endocrinol. 16;344:114384 2023

Evolution of Vertebrate Hormones and Their Receptors: Insights from Non-Osteichthyan Genomes.
Kuraku S, Kaiya H, Tanaka T, Hyodo S.
Annu Rev Anim Biosci. 15;11:163-182 2023

Ghrelin, not corticosterone, is associated with transitioning of phenotypic states in a migratory Galliform.
Marasco V, Kaiya H, Pola G, Fusani L.
Front Endocrinol (Lausanne). 9;13:1058298　2023

Natural Killer Cell-based Immunotherapy Against Glioblastoma.
Morimoto T, Nakazawa T, Maeoka R, Nakagawa I, Tsujimura T, Matsuda R.
Int J Mol Sci. 24 (3), 2111 2023

Capability of Human Dendritic Cells Pulsed with Autologous Induced Pluripotent Stem Cell Lysate to Induce Cytotoxic T Lymphocytes Against HLA-A33-matched Cancer Cells.
Nakazawa T, Maeoka R, Morimoto T, Matsuda R, Nakamura M, Nishimura F, Yamada S, Nakagawa I, Park YS, Nakase H, Tsujimura T.
Int J Mol Sci. 23(21), 12992 2022

Establishment of an efficient ex vivo expansion strategy for human natural killer cells stimulated by defined cytokine cocktail and antibodies against natural killer cell-activating receptors.  
Nakazawa T, Morimoto T, Maeoka R, Matsuda R, Nakamura M, Nishimura F, Yamada S, Nakagawa I, Park YS, Nakase H, Tsujimura T.
Regen Ther. 21:185-191. 2022

Evaluation of comprehensive gene expression and NK cell-mediated killing in Glioblastoma cell line-derived spheroids.
Morimoto T, Nakazawa T, Matsuda R, Nishimura F, Nakamura M, Yamada S, Nakagawa I, Park YS, Tsujimura T, Nakase H.
Cancers. 13(19), 4896 2021

Ex vivo Expanded and Activated Natural Killer Cells Prolong the Overall Survival of Mice with Glioblastoma-like Cell-Derived Tumors.
Shida Y, Nakazawa T, Matsuda R, Morimoto T, Nishimura F, Nakamura M, Maeoka R, Yamada S, Nakagawa I, Park YS, Yasukawa M, Tojo T, Tsujimura T, Nakase H.
Int J Mol Sci. 22(18), 9975 2021

CRISPR–Cas9–mediated TIM3 knockout in human Natural Killer Cells Enhances Growth Inhibitory Effects on Human Glioma Cells.
Morimoto T, Nakazawa T, Matsuda R, Nishimura F, Nakamura M, Yamada S, Nakagawa I, Park YS, Tsujimura T, Nakase H.
Int J Mol Sci. 22(7), 3489 2021

Isolation of adipose tissue-derived stem cells by direct membrane migration and expansion for clinical application.
Matsuo Y, Morita H, Yamagishi H, Nakamura M, Takeshima Y, Nakagawa I, Imanishi J, Tsujimura T.
Hum Cell 2021 34(3):819-824 2021

KHYG-1 Cells With EGFRvIII-specific CAR Induced a Pseudoprogression-like Feature in Subcutaneous Tumours Derived from Glioblastoma-like Cells.
Nakazawa T, Murakami T, Natsume A, Nishimura F, Morimoto T, Matsuda R, Nakamura M, Yamada S, Nakagawa I, Motoyama Y, Park YS, Tsujimura T, Wakabayashi T, Nakase H.
Anticancer Res. 40:3231-3237. 2020

Effect of CRISPR/Cas9-Mediated PD-1-disrupted primary human third-generation CAR-T cells targeting EGFRvIII on in vitro human glioblastoma cell growth.
Nakazawa T, Natsume A, Nishimura F, Morimoto T, Matsuda R, Nakamura M, Yamada S, Nakagawa I, Motoyama Y, Park YS, Tsujimura T, Wakabayashi T, Nakase H.
Cells. 9(4), 998 2020

Ex vivo-expanded highly purified natural killer cells in combination with temozolomide induce antitumor effects in human glioblastoma cells in vitro.
Tanaka Y, Nakazawa T, Nakamura M, Nishimura F, Matsuda R, Omoto K, Shida Y, Murakami T, Nakagawa I, Motoyama Y, Morita H, Tsujimura T, Nakase H.
PLOS ONE. 26;14(3):e0212455 2019

Expression of peptide transporter 1 has a positive correlation in protoporphyrin IX accumulation induced by 5-aminolevulinic acid with photodynamic detection of non-small cell lung cancer and metastatic brain tumor specimens originating from non-small cell lung cancer.
Omoto K, Matsuda R, Nakazawa T, Nishimura F, Nakagawa I, Motoyama Y, Nakamura M, Nakase H et al.
Photodiagnosis Photodyn Ther. 25:309–316. 2019

Novel Human NK Cell Line Carrying CAR Targeting EGFRvIII Induces Antitumor Effects in Glioblastoma Cells.
Murakami T, Nakazawa T, Natsume A, Nishimura F, Nakamura M, Matsuda R, Omoto K, Tanaka Y, Shida Y, Park YS, Motoyama Y, Nakagawa I, Yamada S, Tamura K, Takeshima Y, Takamura Y, Wakabayashi T, Nakase H.
Anticancer Res. 38:5049-5056. 2018

Minodronic Acid in Combination with γδT Cells Induces Apoptosis of Non-small Cell Lung Carcinoma Cell Lines.
Yasukawa M, Nakazawa T, Kawaguchi T, Kawai N, Tsujimura T, Tojo T, Taniguchi S.
Anticancer Res. 36:5883-5886. 2016

Antitumor effects of minodronate, a third-generation nitrogen-containing bisphosphonate, in synergy with γδT cells in human glioblastoma in vitro and in vivo.
Nakazawa T, Nakamura M, Matsuda R, Nishimura F, Park YS, Motoyama Y, Hironaka Y, Nakagawa I, Yokota H, Yamada S, Tamura K, Takeshima Y, Omoto K, Tanaka Y, Ouji Y, Yoshikawa M, Tsujimura T, Nakase H.
J Neurooncol. 129:231-241. 2016

Cytotoxic human peripheral blood-derived γδT cells kill glioblastoma cell lines: implications for cell-based immunotherapy for patients with glioblastoma.
Nakazawa T, Nakamura M, Park YS, Motoyama Y, Hironaka Y, Nishimura F, Nakagawa I, Yamada S, Matsuda R, Tamura K, Sugimoto T, Takeshima Y, Marutani A, Tsujimura T, Ouji N, Ouji Y, Yoshikawa M, Nakase H.
J Neurooncol. 116:31-39. 2014

Characterization and expansion of human peripheral blood γδ T cells.
Tsujimura T, Nakazawa T, Matsuo Y, Imanishi J.
J Kyoto Pref Univ of Med. 118:711-722. 2009

Correlations of sleep disturbance with the immune system in type 2 diabetes mellitus.
Tsujimura T, Matsuo Y, Keyaki T, Sakurada K, Imanishi J.
Diabetes Res Clin Pract. 85:286-292. 2009

Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines.
Furukawa Y, Vu HA, Akutsu M, Odgerel T, Izumi T, Tsunoda S, Matsuo Y, Kirito K, Sato Y, Mano H, Kano Y.
Leukemia. 21:1005-1014.2007

Involvement of IL-10 and Bcl-2 in resistance against an asbestos-induced apoptosis of T cells.
Miura Y, Nishimura Y, Katsuyama H, Maeda M, Hayashi H, Dong M, Hyodoh F, Tomita M, Matsuo Y, Uesaka A, Kuribayashi K, Nakano T, Kishimoto T, Otsuki T.
Apoptosis. 11:1825-1835. 2006

Inhibitory effects of anti-oxidants on apoptosis of a human polyclonal T-cell line, MT-2, induced by an asbestos, chrysotile-A.
Hyodoh F, Takata-Tomokuni A, Miura Y, Sakaguchi H, Hatayama T, Hatada S, Katsuyama H, Matsuo Y, Otsuki T.
Scand J Immunol. 61:442-448. 2005

CISH knockout by CRISPR/Cas9 enhances human peripheral blood-derived NK cell functions against allogeneic glioblastoma.
Nakazawa T, Morimoto T, Maeoka R, Matsuda R, Nishimura F, Tsujimura T, Nakagawa I.
Annual Meeting of International Society of Cell and Gene Therapy (ISCT) 2024, Vancouver, Canada

Characterization of CISH-knockout NK cells derived from human peripheral blood and evaluated the antitumor effects in allogeneic glioblastoma.
Nakazawa T, Morimoto T, Maeoka R, Matsuda R, Nishimura F, Tsujimura T, Nakagawa I.
Annual Meeting of American Association of Immunology (AAI) "IMMUNOLOGY2024", Chicago, USA

Ablation of the intracellular immune checkpoint molecule CIS potentiates antitumor effects against glioblastoma by unleashing the functions of NK cells derived from human peripheral blood.
Nakazawa T, Morimoto T, Maeoka R, Matsuda R, Nishimura F, Nakamura M, Yamada S, Nakagawa I, Park YS, Tsujimura T, Nakase H.
The 51st Annual Meeting of the Japanese Society for Immunology, 2022, Kumamoto

CRISPR–Cas9–mediated TIM3 knockout in human Natural Killer Cells Enhances Growth Inhibitory Effects on Human Glioma Cells.
Morimoto T, Nakazawa T, Matsuda R, Nishimura F, Nakamura M, Yamada S, Nakagawa I, Park YS, Tsujimura T, Nakase H. Annual Meeting of American Association of Immunology ”IMMUNOLOGY2021", Virtual meeting
J Immunol May 1, 2021, 206 (1 Supplement) 68.17

Induction of EGFRvIII-targeting CAR-expressing Natural Killer Cells Derived From Human Induced Pluripotent Stem Cells.
Nakazawa T, Natsume A, Nishimura F, Morimoto T, Matsuda R, Nakamura M, Nakagawa I, Park YS, Tsujimura T, Wakabayashi T, Nakase H.
Keystone symposia Emerging Cell Therapies: Realizing the Vision of NextGen Cell Therapeutics, 2021, Keystone Virtual meeting

Characterization of a novel type NK cell line KHYG-1 carrying EGFRvIII-specific CAR in glioblastoma cells.
Morimoto T, Nakazawa T, Natsume A, Nishimura F, Matsuda R, Murakami T, Nakamura M, Nakagawa I, Motoyama Y, Park YS, Tsujimura T, Wakabayashi T, Nakase H.
Annual Meeting of American Association of Immunology, ”IMMUNOLOGY2020", Hawaii, USA
J. Immunol 2020. 204 (1 Supplement) 170.22

Effect of CRISPR/Cas9-mediated PD-1-disrupted primary human third-generation CAR-T cells targeting EGFRvIII on human glioblastoma cell growth.
Nakazawa T, Morimoto T, Natsume A, Nishimura F, Matsuda R, Murakami T, Nakamura M, Nakagawa I, Motoyama Y, Park YS, Tsujimura T, Wakabayashi T, Nakase H.
Annual Meeting of American Association of Immunology ”IMMUNOLOGY2020", Hawaii, USA
J. Immunol 2020. 204 (1 Supplement) 170.1

Establishment of an efficient ex-vivo expansion method for highly purified human natural killer cells and evaluation of their antitumor activity on glioblastoma.
Nakazawa T, Tanaka Y, Shida Y, Nakamura M, Nishimura F, Matsuda R, Murakami T, Nakagawa I, Motoyama Y, Tsujimura T, Nakase H.
Keystone Symposia: Innate and Non-Classical Immune Cells in Cancer Immunotherapy, 2019, Keystone, USA

Capability of dendritic cells loaded with induced-pluripotent stem cells to induce cancer-responsive T cells from a donor with HLA class I-A33 alleles in vitro.
Nakazawa T, Nishimura F, Matsuda R, Yamashita Y, Nakamura M, Nakagawa I, Motoyama Y, Tsujimura T, Nakase H.
European Association for Cancer Research: Defence is the Best Attack: Immuno-Oncology Breakthroughs, 2019, Barcelona, Spain

Antitumor effects of minodronate, a third-generation nitrogen-containing bisphosphonate, in synergy with γδT cells in human glioblastoma in vitro and in vivo.
Nakazawa T, Nakamura M, Matsuda R, Nishimura F, Tsujimura T, Nakase H et al.
American Association for Cancer Research: Immunobiology of Primary and Metastatic CNS Cancer: Multidisciplinary Science to Advance Cancer Immunotherapy Special Conference, 2018, San Diego, USA

Minodronate exerts antitumor effects against human glioblastoma in cooperation with peripheral blood-derived γδ T cells.
Nakazawa T, Nakamura M, Matsuda R, Park YS, Motoyama Y, Hironaka Y, Nishimura F, Nakagawa I, Tamura K, Takeshima Y, Marutani A, Omoto K, Tanaka Y, Ouji Y, Yoshikawa M, Tsujimura T, Nakase H.
International Conference of Cancer Immunotherapy and Macrophages, 2015, Tokyo

Cytotoxic human peripheral blood-derived γδT cells kill glioblastoma cell lines.
Nakazawa T, Tsujimura T.
The 73rd Annual Meeting of the Japanese Cancer Association, 2014, Yokohama

The effectiveness of valproic acid for malignant glioma in the temozolomide era.
Matsuda R, Nakamura M, Nakazawa T, Tamura K, Yamada S, Nishimura F, Nakagawa I, Motoyama Y, Park YS, Nakase H.
The 10th Meeting of the Asian Society for Neuro-Oncology, 2013, Mumbai

Expansion of human natural killer cells in vitro.
Nakazawa T, Tsujimura T, Imanishi J, Matsuo Y.
The 68th Annual Meeting of the Japanese Cancer Association, 2009, Yokohama

Characterization of expanded γδ T cells derived from human peripheral blood.
Nakazawa T, Tsujimura T, Imanishi J, Matsuo Y.
The 67th Annual Meeting of the Japanese Cancer Association, 2008, Nagoya

Determination of heterogeneity of in vitro expanded peripheral blood γδT cells derived from human peripheral blood.
Shiomi R, Nakazawa T, Tsujimura T, Imanishi J, Matsuo Y.
The 38th Annual Meeting of the Japanese Society for Immunology, 2008, Kyoto

Establishment of regulatory γδT cell line derived from human T cell leukemia virus type I career.
Nakazawa T, Tsujimura T, Imanishi J, Matsuo Y.
The 66th Annual Meeting of the Japanese Cancer Association, 2007, Yokohama

Establishment and characterization of regulatory T cell-like γδT cell line derived from human peripheral blood.
Nakazawa T, Tsujimura T, Imanishi J, Matsuo Y.
The 37th Annual Meeting of the Japanese Society for Immunology, 2007, Tokyo

Expansion of NKT cells and specific cytotoxicity against cell lines derived from multiple myelomas.
Nakazawa T, Tsujimura T, Imanishi J, Matsuo Y.
The 65th Annual Meeting of the Japanese Cancer Association, 2006, Yokohama

Characterization of HIF-1α Knockout Primary Human Natural Killer Cells in Allogeneic Glioblastoma
Nakazawa T, Yamada K, Hayami H, Morimoto T, Matsuda R, Nishimura F, Tsujimura T, Nakagawa I.
Annual Meeting of American Association of Immunology (AAI) "IMMUNOLOGY2025", Hawaii, USA

Characterization of HIF-1α knockout primary human natural killer cells in allogeneic glioblastoma
中澤 務、山田 研吾、速水 宏達、森本 尭之、松田 良介、西村 文彦、辻村 貴弘、中川 一郎
第24回日本再生医療学会総会、2025年、横浜

Efficient feeder-free expansion system for highly purified NK cells derived from human cord blood
中澤 務、森本 尭之、前岡 良輔、松田 良介、西村 文彦、中村 光利、山田 修一、中川 一郎、辻村 貴弘
第23回日本再生医療学会、2024年、新潟

Functional analysis of inhibitory receptors in natural killer cell-based immunotherapy against Glioblastoma.
松田 良介、中澤 務、前岡 良輔、森本 尭之、西村 文彦、中村 光利、辻村 貴弘、中川 一郎
第28回日本がん免疫学会総会、2024年、東京

膠芽腫モデルに対する NK 細胞の抗腫瘍効果の検証と抗 KIR2DL1 抗体の影響
前岡良輔、中澤務、森本尭之、松田良介、西村文彦、中村光利、山田修一、中川一郎、辻村貴弘、中瀬裕之
第41回日本脳腫瘍学会学術集会、2023年、新潟

膠芽腫に対するNK細胞療法の研究開発　- オールドルーキーの帰還 -
前岡良輔、中澤務、松田良介、中村光利、山田修一、辻村貴弘、中川一郎
日本脳神経外科学会第82回学術総会、横浜

CISノックアウトヒト同種NK細胞の膠芽腫に対する抗腫瘍効果
中澤務、前岡良輔、森本尭之、松田良介、中村光利、辻村貴弘
第29回日本遺伝子細胞治療学会学術集会、2023年、大阪

Evaluation of Comprehensive Gene Expression and NK Cell-Mediated Killing in Glioblastoma Cell Line-Derive spheroids.
森本尭之、中澤務、松田良介、西村文彦、中村光利、山田修一、中川一郎、朴永銖、辻村貴弘、中瀬裕之
第27回日本がん免疫学会総会、2023年、三重

Targeting a checkpoint molecule enhances human NK cell functions against allogeneic glioblastoma.
中澤務、前岡良輔、森本尭之、松田良介、中村光利、西村文彦、山田修一、中川一郎、辻村貴弘
日本ゲノム編集学会 第8回大会 、2023年、東京

CIS deletion with CRISPR/Cas9 enhances primary human NK cell functions against allogeneic GBM cells
中澤務、前岡良輔、森本尭之、松田良介、中村光利、西村文彦、山田修一、中川一郎、中瀬裕之、辻村貴弘
第22回日本再生医療学会総会、2023年、京都

CRISPR/Cas9を用いたCIS欠損NK細胞の膠芽腫に対する抗腫瘍効果の検討
前岡良輔, 中澤務, 森本尭之, 松田良介, 西村文彦, 中川一郎, 辻村貴弘, 中瀬裕之
第40回日本脳腫瘍学会学術集会、2022年、千葉

膠芽腫スフェロイドモデルにおける遺伝子発現解析とNK細胞の傷害活性についての検討
森本尭之, 中澤務, 松田良介, 西村文彦, 中村光利, 山田修一, 中川一郎, 朴永銖, 辻村貴弘, 中瀬裕之
第40回日本脳腫瘍学会学術集会、2022年、千葉

CIS deletion by CRISPR/Cas9 enhances human NK cell-mediated antitumor effects in glioblastoma
前岡良輔、中澤務、森本尭之、松田良介、西村文彦、中村光利、山田修一、中川一郎、辻村貴弘、中瀬裕之
第26回日本がん免疫学会総会、2022年、島根

Anti-tumor effect of genuine induced natural killer cells for glioblastoma in vitro and vivo study
松田良介 、中澤務、森本尭之、前岡良輔、西村文彦、中川一郎、辻村貴弘、中瀬裕之
第26回日本がん免疫学会総会、2022年、島根

Natural killer 細胞を用いた膠芽腫に対する細胞移植治療の基礎的研究
松田良介 、中澤務、森本尭之、至田洋一、前岡良輔、 西村文彦、中川一郎、辻村貴弘、中瀬裕之
第22回日本分子脳神経外科学会、2022年、石川

CRISPR-Cas9によるTIM3ノックアウトNK細胞における膠芽腫細胞株への抗腫瘍効果の検討
森本尭之、中澤務、松田良介、西村文彦、中村光利、山田修一、中川一郎、朴永銖、辻村貴弘、中瀬裕之
第39回日本脳腫瘍学会学術集会 、2021年、兵庫

当科における膠芽腫に対するNK細胞療法の開発の歩み
森本尭之、中澤務、松田良介、西村文彦、中村光利、山田修一、中川一郎、朴永銖、辻村貴弘、中瀬裕之
日本脳神経外科学会第80回学術総会 、2021年、山梨

CRISPR-Cas9-Mediated TIM3 knockout in human Natural Killer Cells Enhances Growth Inhibitory Effects on Human Glioma Cells.
森本尭之、中澤務、松田良介、西村文彦、中村光利、山田修一、中川一郎、朴永銖、辻村貴弘、中瀬裕之
第21回日本分子脳神経外科学会 、2021年、京都

The role of PD-1/PD-L1 pathway in anti-tumor effect of genuine induced natural killer cells for glioblastoma in vitro and vivo study
松田良介、中澤務、至田洋一、森本 尭之、西村文彦、中村光利、山田修一、中川一郎、辻村貴弘、中瀬裕之
第25回日本がん免疫学会総会、2021年、和歌山

CRISPR–Cas9–mediated TIM3 knockout in human Natural Killer Cells Enhances Growth Inhibitory Effects on Human Glioma Cells
森本尭之、中澤務、松田良介、西村文彦、中村光利、山田修一、中川一郎、朴永銖、辻村貴弘、中瀬裕之
第25回日本がん免疫学会総会、2021年、和歌山

Efficient blockade of TIM3 by CRISPR-Cas9 in Human Natural killer cells Enhances an antitumor effect in Human Glioblastoma Cells
森本尭之、中澤務、松田良介、西村文彦、中村光利、山田修一、中川一郎、朴永銖、辻村貴弘、中瀬裕之
日本ゲノム編集学会第６回大会、2021年、福岡

当院におけるWT1ペプチド樹状細胞治療の経験
辻村貴弘、中村光利
第1回WT1樹状細胞研究会、2020年、Web会議

Establishment of highly purified human natural killer cells and evaluation of their antitumor activity on glioblastoma
松田良介、中澤務、田中祥貴、至田洋一、中村光利、西村文彦、村上敏春、中川一郎、本山靖、辻村貴弘、中瀬裕之
第23回日本がん免疫学会総会、2019年、高知

膠芽腫に対する高純度NK細胞と免疫チェックポイント阻害薬併用による抗腫瘍効果の検討
至田洋一、中澤務、中村光利、辻村貴弘、森本尭之、田中祥貴、村上敏春、尾本幸治、松田良介、中川一郎、西村文彦、本山靖、朴永銖、中瀬裕之
第20回日本分子脳神経外科学会、2019年、東京

膠芽腫細胞に対する高純度NK細胞とTMZの併用による抗腫瘍効果とその機序の解析
至田洋一、中澤務、中村光利、辻村貴弘、田中祥貴、竹島靖浩、松田良介、田村健太郎、山田修一、中川一郎、西村文彦、横田浩、本山靖、朴永銖、中瀬裕之
第18回日本分子脳神経外科学会学術集会、2017年、山梨

高純度NK細胞を用いた膠芽腫細胞に対する抗腫瘍効果とTMZを用いた併用効果の基礎的検討
田中祥貴、中澤務、中村光利、辻村貴弘、尾本幸治、竹島靖浩、松田良介、田村健太郎、山田修一、中川一郎、西村文彦、横田浩、本山靖、朴永銖、中瀬裕之
第14回日本免疫治療学研究会学術集会、2017年、東京

ミノドロン酸の抗非小細胞肺癌効果の検討
安川元章、東条尚、川口剛史、河合紀和、中澤務、辻村貴弘
第56回日本肺癌学会学術集会、2015年、横浜

膠芽腫細胞株におけるミノドロン酸の抗腫瘍効果の検討
松田良介、中村光利、中澤務、西村文彦、辻村貴弘、中瀬裕之
第12回日本免疫治療学研究会学術集会、2015年、東京

ヒト末梢血由来細胞傷害性γδT細胞は膠芽腫細胞株を殺傷する
中澤務、中村光利、松田良介、朴永銖、本山靖、新靖史、弘中康雄、中川一郎、西村文彦、丸谷明子、王寺典子、辻村貴弘、王寺幸輝、吉川正英、中瀬裕之
第18回日本がん免疫学会総会、2014年、愛媛

ヒト神経膠芽腫細胞株に対するヒト末梢血由来γδT細胞の細胞傷害活性について
中澤務、中村光利、朴永銖、本山靖、弘中康雄、西村文彦、中川一郎、山田修一、松田良介、杉本正、竹島靖浩、丸谷明子、王寺幸輝、吉川正英、辻村貴弘、中瀬裕之
第13回日本分子脳神経外科学会学術集会、2012年、熊本